| Bioactivity | α-Glucosidase-IN-30 (compound 8c) is a potent, orally active, competitive inhibitor against α-glucosidase, with Ki of 40.0 µM and IC50 value of 49.0 µM. α-Glucosidase-IN-30 is non-cytotoxic against the cancer and normal cell lines MCF-7 and HDF, and can be used for Type 2 diabetes study[1]. |
| Target | 49.0 µM (α-glucosidase) |
| Invitro | α-Glucosidase-IN-30 (compound 8c) 对 MCF-7和 HDF 细胞系 (IC50 > 200 μM) 均无细胞毒活性[1]。 0 --> α-Glucosidase-IN-30 相关抗体: |
| Name | α-Glucosidase-IN-30 |
| Formula | C20H19N7O2 |
| Molar Mass | 389.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yousefnejad F, et al. Design, synthesis, in vitro, and in silico evaluations of benzo[d]imidazole-amide-1,2,3-triazole-N-arylacetamide hybrids as new antidiabetic agents targeting α-glucosidase. Sci Rep. 2023;13(1):12397. |